Study of TH104 for itching in primary biliary cholangitis
Part of Digestive system, Skin clinical trials.
This trial tests an experimental drug called TH104 to see if it can reduce itching in people with primary biliary cholangitis. The study will help find out if TH104 is safe and effective for this symptom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary biliary cholangitis (PBC).
- You have moderate to severe itching (rated 4 or higher on a scale of 0 to 10) at screening and on most days during the week before the study starts.
- If you take medications for PBC or itching, you must be on a stable dose for at least 12 weeks before the study starts.
- You must be willing to use effective birth control during the study if you could become pregnant or get someone pregnant.
- You do not have certain other liver diseases or severe liver damage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This trial tests a combination of two experimental drugs (seladelpar and cilofexor) for people with primary biliary cholangitis (PBC) who have not responded well to standard treatment. The goal is to see if these drugs can improve liver health and reduce symptoms.
This trial tests an investigational medicine called linerixibat for people with primary biliary cholangitis (PBC) who have severe itching that hasn't responded to other treatments and who are at risk of serious complications from the itching. It aims to help reduce this itching and improve quality of life.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This study tests a new medication called nemolizumab to see if it can reduce the intense itching caused by certain liver diseases (PBS or PSC). The drug may help block a protein that triggers itch signals, offering relief for people whose current treatments haven't worked well.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.